When did Dianthus Therapeutics report Q4 2024 earnings?

Dianthus Therapeutics (DNTH) reported Q4 2024 earnings on March 11, 2025 before market open.

What were Dianthus Therapeutics's Q4 2024 revenue and EPS?

Dianthus Therapeutics reported revenue of $1.3M and eps of $-0.81 for Q4 2024.

Did Dianthus Therapeutics beat estimates in Q4 2024?

Revenue beat the consensus estimate of $955.2K by $370.8K. EPS beat the consensus estimate of $-0.85 by $0.04.

Where can I find Dianthus Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-037131) directly on SEC EDGAR. The filing index links above go to sec.gov.

Dianthus Therapeutics DNTH Q4 2024 Annual earnings

Reported March 11, 2025 · Before market open

Revenue$1.3MBeat by $370.8K

EPS-$0.81Beat by $0.04

Revenue estimate$955.2K

EPS estimate-$0.85

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$297.2K

EPS estimate-$0.93

Financials

Q4 2024

Income statement

See full

Revenue$1.3M+190%

Operating income-$31.9M-146%

Net income-$28.4M-169%

EPS (diluted)-$0.82—

Balance sheet

See full

Cash & equivalents$22.8M-82.8%

Total debt$1.5M+155%

Total equity$352.5M+109%

Total assets$374.0M+108%

Cash flow

See full

Operating cash flow-$27.4M-132%

CapEx$31.0K+210%

Free cash flow-$27.5M-132%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$645.21M+1,269%

Enterprise value$623.91M+837%

P/S103.5×—

Profitability

See full

Operating margin-1,633.7%—

Net margin-1,362.8%—

FCF margin-1,255.6%—

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0×0.0×

Current ratio15.2×-3.2×

Segments

By product

See full

License$1.0M+41.5%

Versus estimates

Revenue

Q1 2026$463.0KBeat by $59.4K Q4 2025$284.0KMiss by $268.2K Q3 2025$396.0KMiss by $2.1K Q2 2025$193.0KMiss by $671.7K Q1 2025$1.2MBeat by $356.1K

Q4 2024$1.3MBeat by $370.8K

Diluted EPS

Q1 2026-$0.85Beat by $0.32 Q4 2025-$1.43Miss by $0.45 Q3 2025-$0.97Miss by $0.11 Q2 2025-$0.88Miss by $0.02 Q1 2025-$0.82Beat by $0.04

Q4 2024-$0.81Beat by $0.04

Ask the moment Dianthus Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Dianthus Therapeutics report Q4 2024 earnings?: Dianthus Therapeutics (DNTH) reported Q4 2024 earnings on March 11, 2025 before market open.
What were Dianthus Therapeutics's Q4 2024 revenue and EPS?: Dianthus Therapeutics reported revenue of $1.3M and eps of $-0.81 for Q4 2024.
Did Dianthus Therapeutics beat estimates in Q4 2024?: Revenue beat the consensus estimate of $955.2K by $370.8K. EPS beat the consensus estimate of $-0.85 by $0.04.
Where can I find Dianthus Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-037131) directly on SEC EDGAR. The filing index links above go to sec.gov.